Related Experiment Video

Updated: Mar 9, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers

Semir Vranic1, Rebecca Feldman, Zoran Gatalica

  • 1Department of Pathology, University of Sarajevo Clinical Center. semir.vranic@gmail.com.

Bosnian Journal of Basic Medical Sciences
|December 28, 2016
PubMed

Insights

Apocrine breast cancer is rare and typically Her-2/neu positive. This review discusses its molecular traits and new biomarkers for advanced disease, emphasizing personalized treatment strategies.

Area of Science:

  • Oncology
  • Genomics
  • Biomarkers

Background:

  • Apocrine carcinoma of the breast is a rare malignancy.
  • It exhibits distinct molecular features: estrogen receptor-negative, androgen receptor-positive, and frequent Her-2/neu overexpression (~30%).
  • Limited treatment options exist for advanced or metastatic stages.

Purpose of the Study:

  • To review the molecular characteristics of apocrine breast cancer.
  • To discuss emerging theranostic biomarkers for this rare cancer.
  • To highlight the significance of comprehensive molecular profiling for personalized treatment.

Main Methods:

  • Literature review of apocrine breast cancer.
  • Analysis of molecular features and biomarker data.
  • Discussion of current and future therapeutic strategies.

Main Results:

  • Apocrine carcinoma presents a unique receptor profile.
  • Her-2/neu is a common target, but other pathways are implicated.
  • Synergistic and antagonistic molecular events can influence treatment response.

Conclusions:

  • Understanding the molecular landscape of apocrine breast cancer is crucial.
  • Novel theranostic biomarkers offer potential for targeted therapies.
  • Comprehensive profiling is essential for tailoring treatment to individual patients.

More Related Videos

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

24.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K